Plerixafor for Stem Cell Mobilization in Normal Donors
Information source: M.D. Anderson Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Blood And Marrow Transplantation
Intervention: Filgrastim (Drug); Plerixafor (Drug); Apheresis Procedure (Procedure)
Phase: Phase 2
Status: Active, not recruiting
Sponsored by: M.D. Anderson Cancer Center Official(s) and/or principal investigator(s): Chitra M. Hosing, MD, Principal Investigator, Affiliation: M.D. Anderson Cancer Center
Summary
The goal of this clinical research study is to learn if treating stem cell donors with
filgrastim (G-CSF) and plerixafor (MozobilŪ) can cause them to produce a higher number of
blood stem cells than filgrastim by itself. Researchers also want to learn if giving both
of these drugs helps donors produce enough stem cells so that only 1 apheresis procedure
needs to be performed.
Researchers will study if using both drugs lowers the risk of the stem cell transplant
recipients developing severe forms graft-versus-host disease (GVHD). GVHD is a condition in
which transplanted tissue (such as blood stem cells) attacks the tissue of the recipient's
body.
The safety and effectiveness of this drug combination will also be studied.
Filgrastim and plerixafor are both designed to help move or "mobilize" the stem cells from
the bone marrow to the blood.
Clinical Details
Official title: Plerixafor for Stem Cell Mobilization in Normal Donors
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Safety in Mobilizing Peripheral Blood Progenitor Cells (PBPC) in DonorsFeasibility in Mobilizing Peripheral Blood Progenitor Cells (PBPC) in Donors
Detailed description:
Stem Cell Transplant:
You will receive blood stem cells from a donor on this study. You will sign a separate
informed consent for the transplant procedure.
Follow-Up Visits:
About 1, 3, and 6 months after the transplant, an extra sample of bone marrow (about 2
teaspoons) will be collected at the same time as the standard of care bone marrow
aspiration/biopsy procedures. This bone marrow sample will be tested to find out how well
the donated stem cells have been accepted by your body. However, you will not have a
separate bone marrow aspiration/biopsy only to collect bone marrow for this testing.
When you return to the clinic at 6, 9, and 12 months for routine transplant follow-up
visits, the study staff will try to get information on your health status from the clinic
notes in your medical record. If this is not possible, you may receive a phone call from the
study staff to check your health status. These calls will last about 10 minutes.
Length of Treatment:
You will be on study for about 1 year after the transplant (including follow-up contact by
phone, if needed).
You may be taken off study early if you are not able to follow study directions or if you
decide to leave the study.
This is an investigational study. Filgrastim is FDA approved for use in stem cell
collection. Plerixafor is FDA approved for use in patients with multiple myeloma and
non-Hodgkin's lymphoma.
Up to 30 donor and recipient pairs will take part in this study. All will be enrolled at MD
Anderson.
Eligibility
Minimum age: 10 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Donor eligibility: Age >/= 10 years.
2. Donor eligibility: Related donors who met standard eligibility criteria and are
willing to participate in this study.
3. Donor eligibility: Able to provide informed consent.
4. Recipient Eligibility: Patients who are scheduled to undergo an allogeneic related
transplant and whose donors consented to participate in this study.
5. Recipient Eligibility: Able to provide informed consent.
Exclusion Criteria:
1) Donors who are on anti-coagulation or anti-platelet agents are not eligible.
Locations and Contacts
University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States
Additional Information
University of Texas MD Anderson Cancer Center Website
Starting date: October 2013
Last updated: May 4, 2015
|